BevacizumabRecent, repeatedEvidence- NCT07900165 · CytomX Therapeutics · Phase 2 · live · background · “bevacizumab + 5-FU + leucovorin” · registered Oct 2026
- NCT07284849 · Incyte Corporation · Phase 3 · live · background · “Bevacizumab” · registered Dec 2025
- NCT07222800 · Pfizer · Phase 3 · live · comparator · “Bevacizumab” · registered Oct 2025
- NCT06997497 · Merck & Co., Inc · Phase 3 · live · comparator · “Bevacizumab” · registered May 2025
- NCT05983367 · Inspirna, Inc. · Phase 2 · background · “Bevacizumab” · registered Aug 2023
| Hoffmann-La Roche48% of its industry studiesUS: Hoffmann-La Roche (FDA 2004) + 6 othersEU: Hoffmann-La Roche (EMA 2005) + 7 others | 66 studies | 45 studies | comparator 4 · background 8 |
LeucovorinRecent, repeatedEvidence- NCT07900165 · CytomX Therapeutics · Phase 2 · live · background · “bevacizumab + 5-FU + leucovorin” · registered Oct 2026
- NCT07412613 · Akeso · Phase 3 · live · comparator · “Calcium Folinate” · registered Feb 2026
- NCT06997497 · Merck & Co., Inc · Phase 3 · live · background · “Leucovorin/levofolinate calcium” · registered May 2025
- NCT03750786 · Isofol Medical AB · Phase 3 · comparator · “Leucovorin” · registered Nov 2018
- NCT00862784 · Eli Lilly and Company · Phase 2 · background · “Folinic acid” · registered Mar 2009
| Sanofi15% of its industry studiesUS: off-patent, 24 generics marketed | 33 studies | 33 studies | background 8 · comparator 4 |
FluorouracilRecent, repeatedEvidence- NCT07900165 · CytomX Therapeutics · Phase 2 · live · background · “bevacizumab + 5-FU + leucovorin” · registered Oct 2026
- NCT07412613 · Akeso · Phase 3 · live · comparator · “5- Fluorouracil” · registered Feb 2026
- NCT06997497 · Merck & Co., Inc · Phase 3 · live · background · “5-Fluorouracil” · registered May 2025
- NCT02305758 · AbbVie · Phase 2 · background · “Fluorouracil infusion” · registered Dec 2014
- NCT00862784 · Eli Lilly and Company · Phase 2 · background · “5-FU” · registered Mar 2009
| Sanofi20% of its industry studiesUS: off-patent, 19 generics marketed | 33 studies | 33 studies | background 11 · comparator 1 |
Folfox protocolRecent, repeatedEvidence- NCT07284849 · Incyte Corporation · Phase 3 · live · background · “FOLFOX” · registered Dec 2025
- NCT05855200 · GlaxoSmithKline · Phase 3 · live · comparator · “FOLFOX” · registered May 2023
- NCT05480306 · Leap Therapeutics, Inc. · Phase 2 · background · “FOLFOX” · registered Jul 2022
- NCT04068610 · AstraZeneca · Phase 2 · live · background · “FOLFOX” · registered Aug 2019
- NCT03883802 · WntResearch AB · Phase 2 · background · “FOLFOX regimen” · registered Dec 2018
| Hoffmann-La Roche20% of its industry studies | 33 studies | 33 studies | background 4 · comparator 1 |
CapecitabineRecent, repeatedEvidence- NCT07412613 · Akeso · Phase 3 · live · comparator · “Capecitabine” · registered Feb 2026
- NCT06686576 · Qilu Pharmaceutical Co., Ltd. · Phase 3 · live · comparator · “CAPEOX/Capecitabine” · registered Nov 2024
- NCT04607421 · Pfizer · Phase 3 · live · comparator · “Capecitabine” · registered Oct 2020
- NCT00675012 · AGC Biologics S.p.A. · Phase 2 · background · “capecitabine” · registered May 2008
- NCT00398879 · COSCIENS Biopharma Inc. · Phase 2 · background · “Capecitabine” · registered Nov 2006
| Hoffmann-La Roche33% of its industry studiesEU: off-patent, 4 generics authorized | 22 studies | 33 studies | comparator 3 · background 2 |
OxaliplatinRecent, repeatedPhase 4 trial recordedEvidence- NCT07412613 · Akeso · Phase 3 · live · comparator · “Oxaliplatin” · registered Feb 2026
- NCT06997497 · Merck & Co., Inc · Phase 3 · live · background · “Oxaliplatin” · registered May 2025
- NCT00862784 · Eli Lilly and Company · Phase 2 · background · “Oxaliplatin” · registered Mar 2009
- NCT00707889 · AbbVie · Phase 2 · background · “oxaliplatin” · registered Jun 2008
- NCT00112918 · Hoffmann-La Roche · Phase 3 · background · “Oxaliplatin” · registered Jun 2005
| Sanofi35% of its industry studies | 22 studies | 22 studies | background 4 · comparator 1 |
xeloxRecent, repeatedEvidence- NCT06686576 · Qilu Pharmaceutical Co., Ltd. · Phase 3 · live · comparator · “CAPEOX/Capecitabine” · registered Nov 2024
- NCT06567782 · GlaxoSmithKline · Phase 2 · live · background · “CAPEOX” · registered Aug 2024
- NCT05855200 · GlaxoSmithKline · Phase 3 · live · comparator · “CAPEOX” · registered May 2023
- NCT02510118 · Nanjing NingQi Medicine Science and Technology Co., Ltd. · Phase 3 · background · “XELOX” · registered Jul 2015
| AstraZeneca25% of its industry studies | 23 studies | 23 studies | background 2 · comparator 2 |
CAPOX RegimenRecent, repeatedEvidence- NCT06686576 · Qilu Pharmaceutical Co., Ltd. · Phase 3 · live · comparator · “CAPEOX/Capecitabine” · registered Nov 2024
- NCT06567782 · GlaxoSmithKline · Phase 2 · live · background · “CAPEOX” · registered Aug 2024
- NCT05855200 · GlaxoSmithKline · Phase 3 · live · comparator · “CAPEOX” · registered May 2023
| — | 23 studies | 23 studies | background 1 · comparator 2 |
FOLFIRI RegimenRecent, repeatedEvidence- NCT05983367 · Inspirna, Inc. · Phase 2 · background · “FOLFIRI regimen” · registered Aug 2023
- NCT05480306 · Leap Therapeutics, Inc. · Phase 2 · background · “FOLFIRI” · registered Jul 2022
- NCT04793958 · Bristol-Myers Squibb · Phase 3 · live · comparator · “FOLFIRI Regimen” · registered Mar 2021
- NCT00752570 · Amgen · Phase 2 · background · “FOLFIRI” · registered Sep 2008
- NCT00454116 · Sanofi · Phase 2 · background · “FOLFIRI” · registered Mar 2007
| — | 22 studies | 11 study | comparator 1 · background 5 |